Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy, Biologic therapy.

St. James's University Hospital, Leeds, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:5City/State/Province:Leeds
Treatments:Chemotherapy, Biologic therapyHospital:St. James's University Hospital
Drugs:Journal:Link
Date:Dec 2011

Description:

Patients:
This phase 3 study involved women with ovarian cancer who were divided into 2 separate treatment groups. Group A consisted of 764 patients with a median age of 57 years (range of 18-81). Group B also had 764 patients with a median age of 57 years (range of 24-82).

Treatment:
Patients in group A were treated with the chemotherapy agents carboplatin and paclitaxel.

Patients in group B were treated with carboplatin and paclitaxel and the biologic therapy agent bevacizumab.

Toxicities:
There was one treatment-related death in group A due to loss of oxygen to the brain. Grade 3 or higher neutropenia was also reported.

There were 4 treatment-related deaths in group B due to brain hemorrhage, sepsis, and gastrointestinal perforation. Grade 3 or higher hypertension and neutropenia were also reported.

Results:
The median overall survival for groups A and B was 28.8 and 36.6 months, respectively.

Support:
This study was partially supported by the pharmaceutical company Roche.

Correspondence: Dr. Mahesh K.B. Parmar; email: mp@ctu.mrc.ac.uk



Back